We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Study shows long-term safety of gene therapy in Parkinson's disease
News

Study shows long-term safety of gene therapy in Parkinson's disease

Study shows long-term safety of gene therapy in Parkinson's disease
News

Study shows long-term safety of gene therapy in Parkinson's disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Study shows long-term safety of gene therapy in Parkinson's disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

New safety data from a study of patients with advanced Parkinson's disease five years after gene transfer-mediated delivery of the neuroprotective factor neurturin directly to patients' brains reveal no serious adverse events related to the treatment.


See Also: Eye drops deliver gene therapy for brain disorders in mouse study


The encouraging long-term safety profile of the surgically administered adeno-associated virus (AAV2)-neurturin gene therapy is described in an article in Human Gene Therapy. The article is part of a special issue on central nervous system disorders.


In the article, William Marks, Jr., University of California, San Francisco, Tiffany Baumann, Isis Pharmaceuticals (Carlsbad, CA), and Raymand Bartus, RTBioconsultants (San Diego, CA), representing the CERE-120 Study Group, describe the study design, which greatly extended the length of follow-up of the 53 patients evaluated compared to previous studies for the purpose of identifying any safety issues that might present months or years after the treatment.


Don't Miss: Novel gene therapy approach to treat Alzheimer’s


"The longevity of rAAV vector expression makes it particularly useful for treatment of chronic neurodegenerative disorders," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "These long-term data lend support to the evidence that rAAV will prove to be an important platform for treating this highly debilitating disease."


Note: Material may have been edited for length and content. For further information, please contact the cited source.


Mary Ann Liebert, Inc., Publishers   press release


Publication

Marks WJ Jr. et al. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer.   Human Gene Therapy, Published July 18 2016. doi: 10.1089/hum.2015.134


Advertisement